IPAS Novel PPARγ Antagonist – the answer for more effective and safer Type II Diabetes treatment

IPAS researchers have been investigating safer drugs against type two diabetes which are effective at increasing insulin sensitivity without causing side effects. The team has successfully used a number of analytical techniques to determine how these new and improved drugs interact with their target in the body. Their work builds on from previous research undertaken by themselves and others around the globe which focusses on a critical aspect on the development of what can often be a debilitating or even life-threatening condition.

PPARγ in Complex with an Antagonist and Inverse Agonist: A Tumble and Trap Mechanism of the Activation Helix
Rebecca L. Frkic, Andrew C. Marshall, Anne-Laure Blayo, Tara L. Pukala, Theodore M. Kamenecka, Patrick R. Griffin, John B. Bruning
DOI: https://doi.org/10.1016/j.isci.2018.06.012

 

 

Advertisements

Posted on July 11, 2018, in Grants, ipas, IPASnews, Media, news, Research, ResearchNews and tagged , . Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: